Citations

Clear

4847 citation(s) found for "Tu, Eric".

Cervical laminoplasty versus laminectomy and posterior cervical fusion for cervical myelopathy: propensity-matched analysis of 24-month outcomes from the Quality Outcomes Database
Mummaneni, Praveen V. , Chou, Dean , Bydon, Mohamad , Bisson, Erica F. , Shaffrey, Christopher I. , Gottfried, Oren N., Asher, Anthony L. , Coric, Domagoj , Potts, Eric A. , Foley, Kevin T. , Wang, Michael Y. , Fu, Kai-Ming, Virk, Michael S. , Knightly, John J. , Meyer, Scott A., Upadhyaya, Cheerag D., Shaffrey, Mark E., Buchholz, Avery L., Tumialán, Luis M. , Turner, Jay D. , Michalopoulos, Giorgos D. , Sherrod, Brandon A. , Haid, Regis W., Chan, Andrew K. , Michalopoulos, Giorgos , Yang, Eunice, Park, Paul , Agarwal, Nitin

Mayo Clinic

Journal of Neurosurgery: Spine | August 12, 2023 | Volume: 39 | Issue: 5 | Pages: 671-681

10.3171/2023.6.spine23345 | PMID 37728378 Get It

OBJECTIVE Compared with laminectomy with posterior cervical fusion (PCF), cervical laminoplasty (CL) may result in different outcomes for those operated on for cervical spondylotic myelopathy (CSM). The aim of this study was to compare 24-month patient-reported outcomes (PROs) for laminoplasty versus PCF by using the Quality Outcomes Database (QOD) CSM data set. METHODS This was a retrospective study using an augmented data set from the prospectively collected QOD Registry Cervical Module. Patients undergoing laminoplasty or PCF for CSM were included. Using the nearest-neighbor method, the authors performed 1:1 propensity matching based on age, operated levels, and baseline modified Japanese Orthopaedic Association (mJOA) and visual analog scale (VAS) neck pain scores. The 24-month PROs, i.e., mJOA, Neck Disability Index (NDI), VAS neck pain, VAS arm pain, EQ-5D, EQ-VAS, and North American Spine Society (NASS) satisfaction scores, were compared. Only cases in the subaxial cervical region were included; those that crossed the cervicothoracic junction were excluded. RESULTS From the 1141 patients included in the QOD CSM data set who underwent anterior or posterior surgery for cervical myelopathy, 946 (82.9%) had 24 months of follow-up. Of these, 43 patients who underwent laminoplasty and 191 who underwent PCF met the inclusion criteria. After matching, the groups were similar for baseline characteristics, including operative levels (CL group: 4.0 ± 0.9 vs PCF group: 4.2 ± 1.1, p = 0.337) and baseline PROs (p > 0.05), except for a higher percentage involved in activities outside the home in the CL group (95.3% vs 81.4%, p = 0.044). The 24-month follow-up for the matched cohorts was similar (CL group: 88.4% vs PCF group: 83.7%, p = 0.534). Patients undergoing laminoplasty had significantly lower estimated blood loss (99.3 ± 91.7 mL vs 186.7 ± 142.7 mL, p = 0.003), decreased length of stay (3.0 ± 1.6 days vs 4.5 ± 3.3 days, p = 0.012), and a higher rate of routine discharge (88.4% vs 62.8%, p = 0.006). The CL cohort also demonstrated a higher rate of return to activities (47.2% vs 21.2%, p = 0.023) after 3 months. Laminoplasty was associated with a larger improvement in 24-month NDI score (−19.6 ± 18.9 vs −9.1 ± 21.9, p = 0.031). Otherwise, there were no 3- or 24-month differences in mJOA, mean NDI, VAS neck pain, VAS arm pain, EQ-5D, EQ-VAS, and distribution of NASS satisfaction scores (p > 0.05) between the cohorts. CONCLUSIONS Compared with PCF, laminoplasty was associated with decreased blood loss, decreased length of hospitalization, and higher rates of home discharge. At 3 months, laminoplasty was associated with a higher rate of return to baseline activities. At 24 months, laminoplasty was associated with greater improvements in neck disability. Otherwise, laminoplasty and PCF shared similar outcomes for functional status, pain, quality of life, and satisfaction. Laminoplasty and PCF achieved similar neck pain scores, suggesting that moderate preoperative neck pain may not necessarily be a contraindication for laminoplasty.
Core outcomes in nerve surgery: development of a core outcome set for ulnar neuropathy at the elbow
Wilson, Thomas J. , Davis, Gavin A , Guedes, Fernando , Hébert‐Blouin, Marie‐Noëlle, Jack, Megan M. , Jacques, Line , Kretschmer, Thomas , Midha, Rajiv, Puffer, Ross C. , Rasulić, Lukas , Ray, Wilson Z. , Rizk, Elias , Rodríguez-Aceves, Carlos Alberto , Shapira, Yuval, Spinner, Robert J. , Zager, Eric L. , Davis, Gavin A. , Dengler, Nora F. , Mahan, Mark A , Pondaag, Willem , Smith, Brandon W. , Socolovsky, Mariano

Mayo Clinic

Journal of Neurosurgery | August 12, 2023 | Volume: 140 | Issue: 2 | Pages: 489-497

10.3171/2023.6.jns23702 | PMID 37877978 Get It

OBJECTIVE Ulnar neuropathy at the elbow (UNE) is common, affecting 1%–6% of the population. Despite this, there remains a lack of consensus regarding optimal treatment. This is primarily due to the difficulty one encounters when trying to assess the literature. Outcomes are inconsistently reported, which makes comparing studies or developing meta-analyses difficult or even impossible. Thus, there is a need for a core outcome set (COS) for UNE (COS-UNE) to help address this problem. The objective of this study was to utilize a modified Delphi method to develop COS-UNE. METHODS A 5-stage approach was utilized to develop COS-UNE: stage 1, consortium development; 2, literature review to identify potential outcome measures; 3, Delphi survey to develop consensus on outcomes for inclusion; 4, Delphi survey to develop definitions; and 5, consensus meeting to finalize the COS and definitions. The study followed the Core Outcome Set-STAndards for Development (COS-STAD) recommendations. RESULTS The Core Outcomes in Nerve Surgery (COINS) Consortium comprised 21 participants, all neurological surgeons representing 11 countries. The final COS-UNE consisted of 22 data points/outcomes covering the domains of demographic characteristics, diagnostics, patient-reported outcomes, motor/sensory outcomes, and complications. Appropriate instruments, methods of testing, and definitions were set. The consensus minimum duration of follow-up was 6 months, with the consensus optimal timepoints for assessment identified as preoperatively and 3, 6, and 12 months postoperatively. CONCLUSIONS The authors identified consensus data points/outcomes and also provided definitions and specific scales to be utilized to help ensure that clinicians are consistent in their reporting across studies on UNE. This COS should serve as a minimum set of data to be collected in all future neurosurgical studies on UNE. The authors hope that clinicians evaluating ulnar neuropathy will incorporate this COS into routine practice and that future studies will consider this COS in the design phase.
Development and Implementation of an Acute Kidney Injury Remote Patient Monitoring Program: Research Letter
Charkviani, Mariam , Frazee, Erin N. , Pearson, Kristina K., Amberg, Brigid M. , Amundson, Rachel H., Bell, Sarah, Cleveland, Eric J., Kohler, Christopher M., Leuenberger, Angela , Reinschmidt, Karen J. , Kattah, Andrea G. , Frazee, Erin N , Bell, Sarah J. , Daniels, Craig E, Leuenberger, Angela M, Ramirez, David A, Zoghby, Ziad , Kattah, Andrea G , Daniels, Craig , Philpot, Lindsey M. , Ramirez, David A.

Mayo Clinic

Canadian Journal of Kidney Health and Disease | August 11, 2023 | Volume: 10 | Issue: No issue available | Pages: No page available

10.1177/20543581231192746 | PMID 37577175 Get It

Acute kidney injury (AKI) survivors have a dynamic posthospital course which warrants close monitoring. Remote patient monitoring (RPM) could be used to improve quality and efficiency of AKI survivor care. Objective: The objective of this report was to describe the development and preliminary feasibility of an AKI RPM program launched in October 2021. Setting: Academic medical center. Patients: Patients enrolled in the AKI RPM program were those who experienced AKI during a hospitalization and underwent nephrology consultation. Measurements/Methods: At enrollment, patients were provided with home monitoring technology and underwent weekly laboratory assessments. Nurses evaluated the data daily and adhered to prespecified protocols for management and escalation of care if needed. Results: Twenty patients were enrolled in AKI RPM in the first 5 months. Median duration of program participation was 36 (31, 40) days. Eight patients (40%) experienced an unplanned readmission, or an emergency department visit, half (N = 4) of which were attributed to AKI and related circumstances. Of the 9 postgraduation survey respondents, all were satisfied with the RPM program and 89% would recommend RPM to other patients with similar health conditions. Limitations: Acute kidney injury RPM was made possible by the existing infrastructure in our integrated health system and the robust resources available in the Mayo Clinic Center for Digital Health. Such infrastructure may not be universally available which could limit scale and generalizability of such a program. Conclusions: Remote patient monitoring can offer a unique opportunity to bridge the care transition from hospital to home and increase access to quality care for the AKI survivors.
Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial
Pfeiler, Georg , Hlauschek, Dominik , Mayer, Erica L. , Deutschmann, Christine , Martín, Miguel , Loibl, Sibylle , Balić, Marija , Park, Haeseong , Prat, Aleix , Bajetta, Emilio, Balko, Justin M. , Bellet-Ezquerra, Merixtell, Bliss, Judith M. , Burstein, Harold J. , Fohler, Hannes, Haddad, Tufia C. , Jassem, Jacek , Lee, Soo Chin , Los, Maartje , Mamounas, Eleftherios P. , Morris, Patrick G. , Gal‐Yam, Einav Nili , Ring, Alistair , Shepherd, Lois E. , Thomssen, Christoph , Machacek‐Link, Jana, Schurmans, Céline , Huang, Xin , Gauthier, Eric , Fesl, Christian , Dueck, Amylou C. , Gnant, Michael , Investigators, on behalf of the PALLAS Groups and, Cameron, David , Steger, Guenther G. , Bellet, Meritxell , Dueck, A. C. , Martin, Miguel , Zdenkowski, Nicholas , Loibl, Sibylle , Balic, Marija , Park, Haeseong , Isaacs, Claudine , Wrangle, John M , Bliss, Judith , Burstein, Harold J , Cardoso, Fatima , Foukakis, Theodoros , Gelmon, Karen A , Goetz, Matthew P , Haddad, Tufia C , Iwata, Hiroji , Jassem, Jacek , Lee, Soo-Chin , Mamounas, Eleftherios P. , Miller, Kathy D , Munzone, Elisabetta , Gal-Yam, Einav Nili , Shepherd, LE , Singer, Christian F , Thomssen, Christoph , Tseng, Ling-Ming , Valagussa, Pinuccia , Winer, Eric , Wolff, Antonio C , Zoppoli, Gabriele M. , Schurmans, Céline , Huang, Xin , Gauthier, Eric , Fesl, Christian , DeMichele, Angela , Gnant, Michael , Mayer, Erica L , Prat, Aleix , Cameron, David , Strobl, Stephanie , Meisel, Jane Lowe , Isaacs, Claudine , Cardoso, Fátima , Gelmon, Karen A. , Goetz, Matthew P. , Linderholm, Barbro Kristina , Miller, Kathy D. , Singer, Christian F. , Winer, Eric P. , Wolff, Antonio C. , DeMichele, Angela , Investigators, on behalf of the PALLAS Groups and, El-Abed, Sarra , Rugo, Hope S. , Traina, Tiffany A , Werutsky, Gustavo , Wolmark, Norman

Mayo Clinic

Journal of Clinical Oncology | August 9, 2023 | Volume: 41 | Issue: 33 | Pages: 5118-5130

10.1200/jco.23.00126 | PMID 37556775 Get It

PURPOSE BMI affects breast cancer risk and prognosis. In contrast to cytotoxic chemotherapy, CDK4/6 inhibitors are given at a fixed dose, irrespective of BMI or weight. This preplanned analysis of the global randomized PALLAS trial investigates the impact of BMI on the side-effect profile, treatment adherence, and efficacy of palbociclib. METHODS Patients were categorized at baseline according to WHO BMI categories. Neutropenia rates were assessed with univariable and multivariable logistic regression. Time to early discontinuation of palbociclib was analyzed with Fine and Gray competing risk models. Unstratified Cox models were used to investigate the association between BMI category and time to invasive disease-free survival (iDFS). 95% CIs were derived. RESULTS Of 5,698 patients included in this analysis, 68 (1.2%) were underweight, 2,082 (36.5%) normal weight, 1,818 (31.9%) overweight, and 1,730 (30.4%) obese at baseline. In the palbociclib arm, higher BMI was associated with a significant decrease in neutropenia (unadjusted odds ratio for 1-unit change, 0.93; 95% CI, 0.91 to 0.94; adjusted for age, race ethnicity, region, chemotherapy use, and Eastern Cooperative Oncology Group at baseline, 0.93; 95% CI, 0.92 to 0.95). This translated into a significant decrease in treatment discontinuation rate with higher BMI (adjusted hazard ratio [HR] for 10-unit change, 0.75; 95% CI, 0.67 to 0.83). There was no significant improvement in iDFS with the addition of palbociclib to ET in any weight category (normal weight HR, 0.84; 95% CI, 0.63 to 1.12; overweight HR, 1.10; 95% CI, 0.82 to 1.49; and obese HR, 0.95; 95% CI, 0.69 to 1.30) in this analysis early in follow-up (31 months). CONCLUSION This preplanned analysis of the PALLAS trial demonstrates a significant impact of BMI on side effects, dose reductions, early treatment discontinuation, and relative dose intensity. Additional long-term follow-up will further evaluate whether BMI ultimately affects outcome.
Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies
Gorak, Edward J., Otterstatter, Michael , Baghdadi, Tareq Al, Foran, James M. , Liu, Jane Jijun, Gore, Steven D. , Kroft, Steven H. , Saber, Wael , Rollison, Dana E. , Wilson, Steffanie H, Thompson, Jason, Borchert, Christine, Hebert, Donnie, Walker, Mary E. , Padron, Eric , Wilson, Stephanie H. , Gillis, Nancy , Bejar, Rafael , Kroft, Steven H , Zhang, Ling , Sherman, Seth , Sekeres, Mikkael A , Otterstatter, Michael , Baghdadi, Tareq Al , Harrington, Alexandra, Starczynowski, Daniel T. , Zhang, Ling , Moscinski, Lynn C. , Dezern, Amy Elizabeth , Sekeres, Mikkael A.

Mayo Clinic

Blood Advances | August 8, 2023 | Volume: 7 | Issue: 20 | Pages: 6120-6129

10.1182/bloodadvances.2023010061 | PMID 37552083 Get It

Abstract Myelodysplastic neoplasms (MDS) are a collection of hematopoietic disorders with widely variable prognoses and treatment options. Accurate pathologic diagnoses present challenges because of interobserver variability in interpreting morphology and quantifying dysplasia. We compared local clinical site diagnoses with central, adjudicated review from 918 participants enrolled in the ongoing National Heart, Lung, and Blood Institute National MDS Natural History Study, a prospective observational cohort study of participants with suspected MDS or MDS/myeloproliferative neoplasms (MPNs). Locally, 264 (29%) were diagnosed as having MDS, 15 (2%) MDS/MPN overlap, 62 (7%) idiopathic cytopenia of undetermined significance (ICUS), 0 (0%) acute myeloid leukemia (AML) with <30% blasts, and 577 (63%) as other. Approximately one-third of cases were reclassified after central review, with 266 (29%) diagnosed as MDS, 45 (5%) MDS/MPN overlap, 49 (5%) ICUS, 15 (2%) AML with <30%, and 543 (59%) as other. Site miscoding errors accounted for more than half (53%) of the local misdiagnoses, leaving a true misdiagnosis rate of 15% overall, 21% for MDS. Therapies were reported in 37% of patients, including 43% of patients with MDS, 49% of patients with MDS/MPN, and 86% of patients with AML with <30% blasts. Treatment rates were lower (25%) in cases with true discordance in diagnosis compared with those for whom local and central diagnoses agreed (40%), and receipt of inappropriate therapy occurred in 7% of misdiagnosed cases. Discordant diagnoses were frequent, which has implications for the accuracy of study-related and national registries and can lead to inappropriate therapy. This trial was registered at www.clinicaltrials.gov as #NCT05074550.
In Memoriam: Joseph Flood, MD, FACP, MACR, MAPLAR
Matteson, Eric L.

Mayo Clinic

Arthritis & Rheumatology | August 8, 2023 | Volume: 76 | Issue: 1 | Pages: 16-17

10.1002/art.42668 Get It

NCCN Guidelines® Insights: Survivorship, Version 1.2023
Sanft, Tara , Ansbaugh, Shannon, Ballinger, T.J., Demark‐Wahnefried, Wendy , Dickinson, Kristin , Fairman, Nathan, Felciano, Josephine, Flores, Tessa , Gabel, Nicolette , Goldman, Mindy, Henry, N. Lynn , Hill‐Kayser, Christine E. , Koura, Divya, Lee, Kimberly , McDonough, Allison L. , Melisko, Michelle , Mooney, Kathi , Moryl, Natalie , Neuman, Heather B. , Patel, Chirayu G. , Peterson, Lindsay L. , Porpiglia, Andrea S., Rodriguez, Maria Alma , Schapira, Lidia , Smith, Sophia K. , Zee, Phyllis C. , McMillian, Nicole R., Freedman-Cass, Deborah A., Tevaarwerk, Amyé , Henry, N Lynn , Demark-Wahnefried, Wendy , Day, Andrew T. , Armenian, Saro H. , Baker, Kevin Scott , Friedman, Debra L. , Hudson, Melissa M. , Moore, Halle C. F. , O’Connor, Tracey L. , Overholser, Linda , Paskett, Electra D. , Pirl, William F. , Schwartz, Anna L. , Yang, Eric H.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 7, 2023 | Volume: 21 | Issue: 8 | Pages: 792-803

10.6004/jnccn.2023.0041 | PMID 37549906 Get It

The NCCN Guidelines for Survivorship are intended to help healthcare professionals address the complex and varied needs of cancer survivors. The NCCN Guidelines provide screening, evaluation, and treatment recommendations for psychosocial and physical problems resulting from adult-onset cancer and its treatment; recommendations to help promote healthy behaviors and immunizations in survivors; and a framework for care coordination. These NCCN Guidelines Insights summarize recent guideline updates and panel discussions pertaining to sleep disorders, fatigue, and cognitive function in cancer survivors.
Creatinine to Cystatin-C Ratio in Renal Cell Carcinoma: A Clinically Pragmatic Prognostic Factor and Sarcopenia Biomarker
Schmeusser, Benjamin N. , Biermann, Henry, Ali, Adil , Midenberg, Eric, Helman, Talia , Armas‐Phan, Manuel , Nabavizadeh, Reza , Joshi, Shreyas , Bilen, Mehmet Asım , Ogan, Kenneth , Master, Viraj A. , Joshi, Shreyas S, Narayan, Vikram M. , Psutka, Sarah P , Nicaise, Edouard , Patil, Dattatraya , Psutka, Sarah P.

Mayo Clinic

The Oncologist | August 4, 2023 | Volume: 28 | Issue: 12 | Pages: e1219-e1229

10.1093/oncolo/oyad218 | PMID 37540787 Get It

Abstract Introduction Low creatinine to cystatin-C ratio (Cr/Cys-C) may be a biomarker for low-muscle mass. Furthermore, low Cr/Cys-C is associated with decreased overall survival (OS), but to date, has not been examined in patients with renal cell carcinoma (RCC). Our objective is to evaluate associations between low Cr/Cys-C ratio and OS and recurrence-free survival (RFS) in patients with RCC treated with nephrectomy. Methods We performed a retrospective review of patients with RCC treated with nephrectomy. Patients with end-stage renal disease and less than 1-year follow up were excluded. Cr/Cys-C was dichotomized at the median for the cohort (low vs. high). OS and RFS for patients with high versus low Cr/Cys-C were estimated with the Kaplan-Meier method, and associations with the outcomes of interest were modeled using Cox proportional Hazards models. Associations between Cr/Cys-C and skeletal muscle mass were assessed with correlations and logistic regression. Results A total of 255 patients were analyzed, with a median age of 64. Median (IQR) Cr/Cys-C was 1 (0.8-1.2). Low Cr/Cys-C was associated with age, female sex, Eastern Cooperative Oncology Group Performance Status ≥1, TNM stage, and tumor size. Kaplan-Meier and Cox regression analysis demonstrated an association between low Cr/Cys-C and decreased OS (HR = 2.97, 95%CI, 1.12-7.90, P =0.029) and RFS (HR = 3.31, 95%CI, 1.26-8.66, P = .015). Furthermore, a low Cr/Cys-C indicated a 2-3 increase in risk of radiographic sarcopenia. Conclusions Lower Cr/Cys-C is associated with inferior oncologic outcomes in RCC and, pending validation, may have utility as a serum biomarker for the presence of sarcopenia in patients with RCC treated with nephrectomy.
Association between early childhood sleep difficulties and subsequent psychiatric illness
Pease, Eric , Shekunov, Julia , Golebiowski, Raphael, Dang, Vanessa, Arbon, Jake, Lloyd, Robin M. , Baughn, Julie , Romanowicz, Magdalena , Savitz, Samuel T. , Lloyd, Robin, Dang, Vanessa, Pines, Andrew R.

Mayo Clinic

Journal of Clinical Sleep Medicine | August 4, 2023 | Volume: 19 | Issue: 12 | Pages: 2059-2063

10.5664/jcsm.10756 | PMID 37539644 Get It